Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.

George DJ, Martini JF, Staehler M, Motzer RJ, Magheli A, Donskov F, Escudier B, Li S, Casey M, Valota O, Laguerre B, Pantuck AJ, Pandha HS, Patel A, Lechuga M, Ravaud A.

Clin Cancer Res. 2019 Feb 15;25(4):1165-1173. doi: 10.1158/1078-0432.CCR-18-1724. Epub 2018 Nov 6.

PMID:
30401688
2.

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial.

Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, Byun SS, Lee JL, Master V, Jin J, DeBenedetto R, Linke R, Casey M, Rosbrook B, Lechuga M, Valota O, Grande E, Quinn DI.

Ann Oncol. 2018 Dec 1;29(12):2371-2378. doi: 10.1093/annonc/mdy454.

3.

Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study.

Kudo M, Kang YK, Park JW, Qin S, Inaba Y, Assenat E, Umeyama Y, Lechuga MJ, Valota O, Fujii Y, Martini JF, Williams JA, Obi S.

Liver Cancer. 2018 May;7(2):148-164. doi: 10.1159/000484620. Epub 2017 Dec 8.

4.

Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.

Rini BI, Hutson TE, Figlin RA, Lechuga MJ, Valota O, Serfass L, Rosbrook B, Motzer RJ.

Clin Genitourin Cancer. 2018 Aug;16(4):298-304. doi: 10.1016/j.clgc.2018.04.005. Epub 2018 May 4.

PMID:
29853320
5.

Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib.

Rini BI, Escudier B, Martini JF, Magheli A, Svedman C, Lopatin M, Knezevic D, Goddard AD, Febbo PG, Li R, Lin X, Valota O, Staehler M, Motzer RJ, Ravaud A.

Clin Cancer Res. 2018 Sep 15;24(18):4407-4415. doi: 10.1158/1078-0432.CCR-18-0323. Epub 2018 May 17.

PMID:
29773662
6.

Clinical Trial Simulations From a Model-Based Meta-Analysis of Studies in Patients With Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy.

Zierhut ML, Chen Y, Pithavala YK, Nickens DJ, Valota O, Amantea MA.

CPT Pharmacometrics Syst Pharmacol. 2016 May;5(5):274-82. doi: 10.1002/psp4.12078. Epub 2016 May 15.

7.

A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma.

English PA, Williams JA, Martini JF, Motzer RJ, Valota O, Buller RE.

Future Oncol. 2016 Jan;12(2):175-82. doi: 10.2217/fon.15.290. Epub 2015 Dec 17.

8.

Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma.

Kang YK, Yau T, Park JW, Lim HY, Lee TY, Obi S, Chan SL, Qin S, Kim RD, Casey M, Chen C, Bhattacharyya H, Williams JA, Valota O, Chakrabarti D, Kudo M.

Ann Oncol. 2015 Dec;26(12):2457-63. doi: 10.1093/annonc/mdv388. Epub 2015 Sep 18.

PMID:
26386123
9.

Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer.

Oh DY, Doi T, Shirao K, Lee KW, Park SR, Chen Y, Yang L, Valota O, Bang YJ.

Cancer Res Treat. 2015 Oct;47(4):687-96. doi: 10.4143/crt.2014.225. Epub 2015 Feb 12.

10.

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.

Motzer RJ, Hutson TE, Hudes GR, Figlin RA, Martini JF, English PA, Huang X, Valota O, Williams JA.

Cancer Chemother Pharmacol. 2014 Oct;74(4):739-50. doi: 10.1007/s00280-014-2539-0. Epub 2014 Aug 7.

11.

Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer.

Lee KW, Park SR, Oh DY, Park YI, Khosravan R, Lin X, Lee SY, Roh EJ, Valota O, Lechuga MJ, Bang YJ.

Invest New Drugs. 2013 Dec;31(6):1547-58. doi: 10.1007/s10637-013-0032-y. Epub 2013 Oct 4.

PMID:
24091982
12.

Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.

Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan J, Valota O, Martell B, Hariharan S, Figlin RA.

J Clin Oncol. 2012 Apr 20;30(12):1371-7. doi: 10.1200/JCO.2011.36.4133. Epub 2012 Mar 19.

PMID:
22430274
13.

Ongoing phase I and II studies of novel anthracyclines.

Sessa C, Valota O, Geroni C.

Cardiovasc Toxicol. 2007;7(2):75-9. Review.

PMID:
17652808
14.

Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validation.

Moneta D, Geroni C, Valota O, Grossi P, de Jonge MJ, Brughera M, Colajori E, Ghielmini M, Sessa C.

Eur J Cancer. 2003 Mar;39(5):675-83.

PMID:
12628848
15.

Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours.

de Jonge MJ, Verweij J, van der Gaast A, Valota O, Mora O, Planting AS, Mantel MA, Bosch SV, Lechuga MJ, Fiorentini F, Hess D, Sessa C.

Eur J Cancer. 2002 Dec;38(18):2407-15.

PMID:
12460785
16.

A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study.

Fokkema E, Verweij J, van Oosterom AT, Uges DR, Spinelli R, Valota O, de Vries EG, Groen HJ.

Br J Cancer. 2000 Feb;82(4):767-71.

17.

Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival.

Miotti S, Negri DR, Valota O, Calabrese M, Bolhuis RL, Gratama JW, Colnaghi MI, Canevari S.

Int J Cancer. 1999 Feb 19;84(1):62-8.

18.

Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation.

Jacobs N, Mazzoni A, Mezzanzanica D, Negri DR, Valota O, Colnaghi MI, Moutschen MP, Boniver J, Canevari S.

Cancer Immunol Immunother. 1997 Jul;44(5):257-64.

19.

Anti-idiotypic response to antigrowth factor receptor monoclonal antibodies.

Tosi E, Valota O, Canevari S, Adobati E, Casalini P, Perez P, Colnaghi MI.

Eur J Cancer. 1996 Mar;32A(3):498-505.

PMID:
8814698
20.

In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody.

Negri DR, Tosi E, Valota O, Ferrini S, Cambiaggi A, Sforzini S, Silvani A, Ruffini PA, Colnaghi MI, Canevari S.

Br J Cancer. 1995 Oct;72(4):928-33.

21.

Anti-tumor efficacy of an anti-epidermal-growth-factor-receptor monoclonal antibody and its F(ab')2 fragment against high- and low-EGFR-expressing carcinomas in nude mice.

Tosi E, Valota O, Negri DR, Adobati E, Mazzoni A, Meazza R, Ferrini S, Colnaghi MI, Canevari S.

Int J Cancer. 1995 Sep 4;62(5):643-50.

PMID:
7665239
22.

Unidirectional potentiation of binding between two anti-FBP MAbs: evaluation of the involved mechanisms.

Casalini P, Mezzanzanica D, Valota O, Adobati E, Tomassetti A, Colnaghi MI, Canevari S.

J Cell Biochem. 1995 May;58(1):47-55.

PMID:
7642722
23.

Ovarian carcinoma therapy with monoclonal antibodies.

Canevari S, Miotti S, Bottero F, Valota O, Colnaghi MI.

Hybridoma. 1993 Oct;12(5):501-7. Review. No abstract available.

PMID:
8300122

Supplemental Content

Loading ...
Support Center